Inhaled Nitric Oxide for Preventing Progression in COVID-19

Summary

This is a pilot randomized-controlled (2:1) open label investigation of inhaled NO to prevent progression to more advanced disease in 42 hospitalized patients with COVID-19, at risk for worsening, based on baseline systemic oxygenation and 2 or more of the major risk factors of age \> 60 years, type II DM, hypertension, and obesity.

Timeline

Start

2020-05-12

Primary completion

2020-11-23

Completion

2020-11-23

Drugs

Indications